Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Low density lipoprotein induces upregulation of vasoconstrictive endothelin type B receptor expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A Validated Echocardiographic Risk Model for Predicting Outcome Following ST-segment Elevation Myocardial Infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Post-systolic shortening predicts heart failure following acute coronary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between layer-specific global longitudinal strain and adverse outcomes following acute coronary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Raffaele Piccolo
  • Ingo Eitel
  • Gennaro Galasso
  • Allan Zeeberg Iversen
  • Youlan L Gu
  • Alberto Dominguez-Rodriguez
  • Bart J G L de Smet
  • Karim D Mahmoud
  • Pedro Abreu-Gonzalez
  • Holger Thiele
  • Federico Piscione
Vis graf over relationer

BACKGROUND: Although intracoronary abciximab failed to improve prognosis compared with intravenous route in unselected ST-segment elevation myocardial infarction (STEMI) patients, little is known about the role of intracoronary abciximab in diabetic patients.

OBJECTIVES: To evaluate the efficacy of intracoronary abciximab administration in diabetic patients with STEMI undergoing primary percutaneous coronary intervention (PCI).

METHODS: Reperfusional and clinical outcomes of intracoronary abciximab compared with intravenous bolus abciximab according to diabetic status were evaluated in a pooled analysis of five randomized trials including 3158 STEMI patients. The primary clinical endpoint of the study was the composite of death or reinfarction at 30-day follow-up.

RESULTS: Among 584 diabetic patients (18.5%), the composite of death or reinfarction was significantly reduced with intracoronary abciximab compared to intravenous abciximab (4.7% vs. 8.8%; rate ratio [RR], 0.50; 95% confidence intervals [CI], 0.26-0.99; p=0.04), driven by numerically lower deaths (3.7% vs. 6.4%; RR, 0.56; 95% CI, 0.26-1.20; p=0.13). Moreover, a significant reduction in definite or probable stent thrombosis was observed in patients receiving intracoronary abciximab (1% vs. 3.5%; RR, 0.27; 95% CI, 0.07-0.99; p=0.04). Although formal tests for interaction were not significant, no clinical benefit was apparent in the cohort of STEMI patients without diabetes (n=2574).

CONCLUSIONS: In diabetic patients with STEMI undergoing primary PCI, intracoronary abciximab may improve clinical outcomes as compared with standard intravenous use. These findings require confirmation in a dedicated randomized trial.

OriginalsprogEngelsk
TidsskriftVascular Pharmacology
Vol/bind73
Sider (fra-til)32-7
Antal sider6
ISSN1537-1891
DOI
StatusUdgivet - okt. 2015

ID: 46237328